Eric Sauvage

Dr. Eric Sauvage


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2008 in FEMS Microbiology Reviews
Verified
Journal Article
Open access
PDF file
ESEric Sauvage
Eric Sauvage
FKFrédéric Kerff
Frédéric Kerff
MTMohammed Terrak
Mohammed Terrak
JUAN ALFONSO Ayala SerranoJUAN ALFONSO Ayala Serrano
JUAN ALFONSO Ayala Serrano
PCPaulette Charlier
Paulette Charlier
Penicillin-binding proteins (PBPs) have been scrutinized for over 40 years. Recent structural information on PBPs together with the ongoing long-term

17 February 2016 in Antibiotics
Verified
Journal Article
Open access
PDF file
ESEric Sauvage
Eric Sauvage
MTMohammed Terrak
Mohammed Terrak
Peptidoglycan (PG) is an essential macromolecular sacculus surrounding most bacteria. It is assembled by the glycosyltransferase (GT) and transpeptidase (TP) activities of multimodular penicillin-binding proteins (PBPs) within multiprotein complex machineries. Both activities are essential for the synthesis of a functional stress-bearing PG shell. Although good progress has been made in terms of the functional and structural understanding of GT, finding a clinically useful antibiotic against them has been challenging until now. In contrast, the TP/PBP module has been successfully targeted by β-lactam derivatives, but the extensive use of these antibiotics has selected resistant bacterial strains that employ a wide variety of mechanisms to escape the lethal action of these antibiotics. In addition to traditional β-lactams, other classes of molecules (non-β-lactams) that inhibit PBPs are now emerging, opening new perspectives for tackling the resistance problem while taking advantage of these valuable targets, for which a wealth of structural and functional knowledge has been accumulated. The overall evidence shows that PBPs are part of multiprotein machineries whose activities are modulated by cofactors. Perturbation of these systems could lead to lethal effects. Developing screening strategies to take advantage of these mechanisms could lead to new inhibitors of PG assembly. In this paper, we present a general background on the GTs and TPs/PBPs, a survey of recent issues of bacterial resistance and a review of recent works describing new inhibitors of these enzymes.

24 October 2012 in Molecules
Verified
Journal Article
Open access
PDF file
AZAstrid Zervosen
Astrid Zervosen
ESEric Sauvage
Eric Sauvage
JFJean-Marie Frère
Jean-Marie Frère
PCPaulette Charlier
Paulette Charlier
ALAndré Luxen
André Luxen
The widespread use of β-lactam antibiotics has led to the worldwide appearance of drug-resistant strains. Bacteria have developed resistance to β-lactams by two main mechanisms: the production of β-lactamases, sometimes accompanied by a decrease of outer membrane permeability, and the production of low-affinity, drug resistant Penicillin Binding Proteins (PBPs). PBPs remain attractive targets for developing new antibiotic agents because they catalyse the last steps of the biosynthesis of peptidoglycan, which is unique to bacteria, and lies outside the cytoplasmic membrane. Here we summarize the “current state of the art” of non-β-lactam inhibitors of PBPs, which have being developed in an attempt to counter the emergence of β-lactam resistance. These molecules are not susceptible to hydrolysis by β-lactamases and thus present a real alternative to β-lactams. We present transition state analogs such as boronic acids, which can covalently bind to the active serine residue in the catalytic site. Molecules containing ring structures different from the β-lactam-ring like lactivicin are able to acylate the active serine residue. High throughput screening methods, in combination with virtual screening methods and structure based design, have allowed the development of new molecules. Some of these novel inhibitors are active against major pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and thus open avenues new for the discovery of novel antibiotics.

1 July 2002 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
ESEric Sauvage
Eric Sauvage
FKF. Kerff
F. Kerff
EFE. Fonzé
E. Fonzé
RHR. Herman
R. Herman
BSB. Schoot
B. Schoot
PCP. Charlier
P. Charlier

29 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEric Sauvage
Eric Sauvage
ADAdeline Derouaux
Adeline Derouaux
CFClaudine Fraipont
Claudine Fraipont
MJMarine Joris
Marine Joris
RHRaphaël Herman
Raphaël Herman
PCPaulette Charlier
Paulette Charlier
In Escherichia coli, penicillin-binding protein 3 (PBP3), also known as FtsI, is a central component of the divisome, catalyzing cross-linking of the cell wall peptidoglycan during cell division. PBP3 is mainly periplasmic, with a 23 residues cytoplasmic tail and a single transmembrane helix. We have solved the crystal structure of a soluble form of PBP3 (PBP357–577) at 2.5 Å revealing the two modules of high molecular weight class B PBPs, a carboxy terminal module exhibiting transpeptidase activity and an amino terminal module of unknown function. To gain additional insight, the PBP3 Val88-Ser165 subdomain (PBP388–165), for which the electron density is poorly defined in the PBP3 crystal, was produced and its structure solved by SAD phasing at 2.1 Å. The structure shows a three dimensional domain swapping with a β-strand of one molecule inserted between two strands of the paired molecule, suggesting a possible role in PBP357–577 dimerization.

1 August 2007 in Journal of Molecular Biology
Verified
Journal Article
Closed access
ESEric Sauvage
Eric Sauvage
CDColette Duez
Colette Duez
RHRaphaël Herman
Raphaël Herman
FKFrédéric Kerff
Frédéric Kerff
SPStephanie Petrella
Stephanie Petrella
PCPaulette Charlier
Paulette Charlier